NCT03206749View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

June 29, 2017

Primary Completion Date

December 1, 2017

Study Completion Date

December 8, 2017

Conditions
Acute Pain
Interventions
DRUG

VX-150

Participants received VX-150 1500 milligram (mg) as first dose, followed by VX-150 750 mg dose every 12 hours (q12h) for 2 days.

DRUG

HB/APAP

Participants received HB 5 mg/APAP 325 mg every 6 hours (q6h) for 2 days.

DRUG

Placebo

Participants received placebo matched to VX-150 and HB/APAP for 2 days.

Trial Locations (4)

84124

Jean Brown Research, Salt Lake City

85023

Arizona Research Center, Phoenix

91105

Lotus Clinical Research, Pasadena

92801

Anaheim Clinical Trials, Anaheim

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT03206749 - A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | Biotech Hunter | Biotech Hunter